| |
Pharmacy Correspondence Programs
Multi-Theme Courses
Each volume contains valuable lessons on a variety of topics important to your practice. Three interesting volumes are available from which to choose.
Please pay special attention to expiration dates.
Volume 34 (16 CE hrs)
Price - $60 per volume
Must submit for CE credit by 03/15/2011
Lesson 1. Pharmacist-Delivered Tobacco Cessation
4 contact hours, 018-999-08-701-H01
Author: Larry A. Dent, Pharm.D., BCPS, University of Montana Skaggs School of Pharmacy
Educational Goals: (i) describe prevalence and epidemiology of tobacco use and discuss health risks, environmental effects, economic burden. (ii) explain the benefits of smoking cessation, list components of nicotine addiction. (iii) apply tobacco cessation strategies, counsel in pharmacotherapy. (iv) recognize benefits, appropriate use, side effects, duration, monitor drug therapies, identify components of cognitive and behavioral change counseling.
Lesson 2. Patient Centered Care: Pharmacist Adult Vaccination
4 contact hours, 018-999-08-702-H01
Authors: Beverly A. Sullivan, Pharm.D. & Kerri Kilgore, Pharm.D., University of Wyoming School of Pharmacy
Educational Goals: (i) identify current recommended adult vaccines, storage, overall safety and management of adverse effects. (ii) recognize and describe the proper administration of vaccinations in adults. (iii) describe process to screen adults seeking vaccination and to document administration. (iv) identify pharmacist liability in provision of adult vaccinations.
Lesson 3. Principles of Obesity Management and Weight Control
4 contact hours, 018-999-08-703-H01
Authors: Judy T. Chen, Pharm.D., BCPS, & Amy Heck Sheehan, Pharm.D., Purdue University School of Pharmacy; Devra K. Dang, Pharm.D., University of Connecticut School of Pharmacy;
Educational Goals: (i) explain the epidemiological impact and discuss implications of overweight and obesity. (ii) understand theories regarding development of obesity, identify the diagnostic criteria for overweight and obesity. (iii) assess patients risk-status and develop treatment goals for weight loss and weight maintenance, evaluating the role of nonpharmacological interventions, dietary supplements, and surgery. (iv) Evaluate the role of pharmacological interventions in weight loss therapy based on patient-specific characteristics, designing an appropriate treatment plan and treatment-specific monitoring plan.
Lesson 4. Counseling Patients with Minor Dermatological Conditions
4 contact hours, 018-999-08-704-H01
Author: Steven Pray, Ph.D., D.Ph., Southwestern Oklahoma State University College of Pharmacy
Educational Goals: (i) recognize dermatological conditions (ii) identify patients with dermatological conditions amenable to self-therapy, and those that require referral (iii) choose appropriate nonprescription therapy for various dermatological conditions (iv) appropriately counsel patients when recommending nonprescription products .
Volume 33
Price - $50 per volume
Must submit for CE credit by 03/01/2010
Number 1. New Drugs: A Practical Guide for Pharmacists
4.0 contact hours, 018-999-07-701-H01
Author: Carroll L. Ramos, R.Ph., Ph.D., Southwestern Oklahoma State University, Weatherford, OK
Educational Goals: (i) identify the pharmacological and/or therapeutic classification. (ii) Describe the approved indication. (iii) Understand the basic mechanism of action. (iv) Describe common adverse effects. (v) Recognize clinically relevant drug interactions. (vi) Discuss important patient information. (vii) Recognize an appropriate dosage regimen.
Number 2. New Therapeutic Options in the Management of Type 2 Diabetes
4.0 contact hours, 018-999-07-702-H01
Author: Betsy Carlisle, Pharm.D., CDE, Brackenridge Hospital, Austin, TX.
Educational Goals: (i) Identify the action patterns of the newer insulins: detemir (Levemir), glulisine (Apidra) and inhaled insulin (Exubera) and their role in basal-bolus insulin regimens. (ii) Understand the role of the new incretin mimetic exenatide (Byetta) in addressing insulin resistance and beta-cell dysfunction. (iii) Describe the potential for pramlintide (Symlin), a synthetic amylin analogue, to complement the action of insulin by reducing glucagon secretion, affectin satiety and slowing gastrointestinal emptying.
Number 3. Therapeutic Strategies for Hypertension
4.0 contact hours, 018-999-07-703-H01
Author: Alan J. Zillich, Pharm.D. Purdue University, Indianapolis, IN
Educational Goals: (i)Delineate the epidemiologic impact of hypertension on society. (ii) Understand hypertension pathophysiology and related clinical sequelae. (iii) Identify the stages of hypertension outlined by the Seventh Joint national Committee on the Prevention, Detection, and Treatment of High Blood Pressure (JNC-7). (iv) Compare and contrast the mechanisms of action for antihypertensive medications. (v) Construct treatment plans for a patient with hypertension and concomitant disease states. (vi) Evaluate patient-specific information and scientific evidence to support appropriate pharmacologic and non-pharmacologic therapies. (vii) Develop specific educational messages for a patient with hypertension.
Number 4. The Metabolic Syndrome
4.0 contact hours, 018-999-07-704-H01
Author: Joan M. Rider, B.S., Pharm.D., BCPS, CDE, FMPA, Ferris State University, Grand Rapids, MI
Educational Goals: (i) Define the metabolic Syndrome (MetS) and its relationship to the development and management of cardiovascular disease and type 2 diabetes mellitus (ii) Discuss the health factors that make up the MetS. (iii) Deliberate the role of inflammation, thrombosis and high sensitivity-complement reactive protein (hs-CRP) in the MetS. (iv) Determine aggressive treatment options for the abnormal health components that lead to Cardiometabolic Risk (CMR).
Volume 32
Price - $40 per volume
Must submit for CE credit by 03/01/2009
Number 1. Anxiety Disorders
4 contact hours, 018-999-06-701-H01
Author: E. Ben Welch, III, Pharm.D., Southwestern Oklahoma State University
Educational Goals: (i) identify which psychiatric disorders are classified as anxiety disorders (ii) describe the signs and symptoms of the various anxiety disorders (iii) identify which antidepressants may be used to treat anxiety disorders (iv) formulate a rational clinical approach for the treatment of each of these anxiety disorders. (v) recognize patient educational considerations dealing with anxiety disorders.
Number 2. Osteoporosis
4 contact hours, 018-999-06-702-H01
Author: Donald R. Miller, Pharm.D., North Dakota State University
Educational Goals: (i) describe normal bone physiology (ii) contrast different methods of evaluating bone density (iii) list causes and risk factors associated with osteoporosis (iv) suggest preventative measures for osteoporosis (v) formulate treatment goals for osteoporosis patients (vi) describe treatment options for osteoporosis (vii) choose appropriate therapy for patients based on patient and drug factors (viii) describe proactive steps that pharmacists can take to provide pharmaceutical care for osteoporosis patients.
Number 3. Update on Pharmacy Law
4 contact hours, 018-999-06-703-H03
Author: Alan R. Spies, R.Ph., J.D., M.B.A., Sanford University
Educational Goals: (i) describe recent changes, both actual and proposed, to the Controlled Substances Act (ii) understand the legal implications involved with a pharmacist's refusal to fill a prescription (iii) identify and rectify potential sexual harassment violations as the relate to Title VII of the Civil Rights Act.
Number 4. Chronic Kidney Disease
4 contact hours, 018-999-06-704-H01
Author: Cynthia A. Naughton, Pharm.D., BCPS, North Dakota State University
Educational Goals: (i) distinguish between mild, moderate, and severe CKD (ii) identify risk factors for CKD and explain their impact on the development and progression of the disease (iii) recommend interventions to control CKD progression and improve outcomes (iv) recommend interventions to prevent and treat complications of CKD.
Single-Theme Courses
NONE CURRENTLY AVAILABLE
|
